Drugs / Andecaliximab
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03631836 | Jan 2019 → Jan 2022 | glioblastoma | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 1 | NCT02862535 | Sep 2016 → Oct 2019 | gastric adenocarcinoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT02209987 | Aug → Oct 2014 | ulcerative colitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02176876 | Aug 2014 → Apr 2015 | rheumatoid arthritis | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02077465 | Mar → Oct 2014 | chronic obstructive pulmonary disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01803282 | Mar 2013 → Apr 2019 | breast cancer, colorectal cancer, gastroesophageal cancer, non-small cell lung carcinoma +1 | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01831427 | Mar 2013 → Jan 2015 | ulcerative colitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07024407 | May → Dec 2025 overdue | hyperostosis | Ashibio Inc | Recruiting | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT02862574 | Dec 2016 → Jun 2017 | rheumatoid arthritis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT02759562 | Nov 2016 → Jul 2017 | cystic fibrosis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT02864381 | Sep 2016 → Nov 2017 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Gilead Sciences | Completed | Missed primary |
| Phase 2 | NCT02405442 | Apr 2015 → Nov 2016 | Crohn disease | Gilead Sciences | Terminated | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02520284 | Sep 2015 → Sep 2016 | ulcerative colitis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02545504 | Oct 2015 → May 2019 | gastric adenocarcinoma | Gilead Sciences | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06508021 Comparator | Oct 2024 → Feb 2029 expected | fibrodysplasia ossificans progressiva | Ashibio Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | Ashibio Inc | Results āshibio Reports Promising Preclinical Data for Two First-in-Class Antibodies Targeting Debilitating Bone Disorders at ASBMR Meeting ashibio.com ↗
“The data we presented at ASBMR highlight the therapeutic potential of our first-in-class investigative antibodies vantictumab and andecaliximab in disease-relevant mouse models” said Victoria Smith, PhD, Chief Scientific Officer of āshibio. |
| 2016-09-21 | Gilead Sciences | Results Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis gilead.com ↗
The DMC recommended that the study be terminated early due to meeting the pre-specified futility and efficacy criteria. |
All press releases naming this drug 4 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Andecaliximab | “Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the pathogenesis of rheumatoid...” PMID 29287749 ↗ Dec 2017 |
| Known as | ADX | “This study evaluated andecaliximab (ADX), an inhibitor of MMP9, in combination with nivolumab (NIVO), for the treatment of advanced gastric cancer.” PMID 34893523 ↗ Dec 20211“Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9)” PMID 35773363 ↗ Jun 2022 |
| Known as | GS-5745 | “Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the pathogenesis of rheumatoid...” PMID 29287749 ↗ Dec 20174“To assess the pharmacokinetics (PK) of GS-5745 (andecaliximab) in participants with moderate to severe UC.” NCT01831427 ↗ “Monoclonal Antibody GS5745 may overcome resistance to bevacizumab through a specific inhibition of MMP9.” NCT03631836 ↗ “Monoclonal Antibody (GS) 5745 is specifically directed against MMP9.” NCT03631836 ↗ |
| Action | Inhibit | “Matrix Metalloproteinase-9 Inhibitor” PMID 29287749 ↗ Dec 2017 |
| Modality | Monoclonal antibody | “a monoclonal antibody targeting MMP9” PMID 29691300 ↗ Apr 2018 |
| Route | Intravenous | “Administered intravenous infusion” NCT01803282 ↗ |
| Target | MMP9 | “against matrix metalloproteinase-9 (MMP9)” PMID 29287749 ↗ Dec 2017 |